106 Commerce Street, Suite 105
Lake Mary, FL 32746
TEL: 407.878.7606 • FAX: 407.878.7611
For additional copies, order at GuidelineCentral.com
Copyright © 2020 All rights reserved
ASCOPARP08203
Disclaimer
is pocket guide is derived om recommendations in the American Society of Clinical Oncology
Guideline. is resource is a practice tool based on ASCO
®
practice guidelines and is not intended
to substitute for the independent professional judgment of the treating physician. Practice guidelines
do not account for individual variation among patients. is pocket guide does not purport to
suggest any particular course of medical treatment. Use of the practice guidelines and this resource
are voluntary. e practice guidelines and additional information are available at www.asco.org/
gynecologic-cancer-guidelines. Copyright © 2020 by American Society of Clinical Oncology. All
rights reserved.
Abbreviations
ASCO, American Society of Clinical Oncolog y; CT, carboplatin and paclitaxel; BRCAm,
BRCA1/2 mutation; BRCAwt, BRCA1/2 wild-type; EOC, epithelial ovarian cancer; PARPi,
poly(ADP-ribose) polymerase inhibitors
Source
William P. Tew, MD; Christina Lacchetti, MHSc; Annie Ellis, et al. (2020). PARP Inhibitors
in the Management of Ovarian Cancer: ASCO Guideline. J Clin Oncol, doi: 10.1200/
JCO.20.01924
Recommendation Grading
Type Benefit/harm Evidence Quality
Strength of
Recommendation
EB Evidence-
based
B Benefits
outweigh
harms
H High Strong
CB
Consensus-
based
H Harms
outweigh
benefits
I Intermediate Moderate
IC Informal
consensus
B/H Benefit equals
harm
L Low Weak
NB No benefit Ins Insufficient
ASCO believes that cancer clinical trials are vital to inform medical decisions and
improve cancer care and that all patients should have the opportunity to participate.
Additional information, which may include data supplements, slide sets, and other clinical
tools and resources, is available at www.asco.org/g ynecologic-cancer-guidelines.
